Key Highlights
- IDEAYA Biosciences unveiled successful Phase 2/3 data for its darovasertib-crizotinib combination targeting metastatic uveal melanoma
- The treatment achieved median progression-free survival of 6.9 months compared to just 3.1 months with standard therapy
- The combination therapy reduced disease progression risk by 58% versus current standard treatment
- Response rates reached 37.1% with the combo versus only 5.8% for standard care — the combination arm recorded 5 complete responses while the control arm had zero
- The company anticipates submitting its New Drug Application (NDA) to the FDA during the latter half of 2026
Shares of IDEAYA Biosciences (IDYA) experienced a significant rally during Monday’s premarket session following the biotechnology company’s announcement of encouraging Phase 2/3 clinical trial outcomes for a dual-therapy approach treating metastatic uveal melanoma — an uncommon and challenging-to-manage cancer originating in the eye.
IDEAYA Biosciences, Inc., IDYA
The clinical study evaluated darovasertib in combination with crizotinib. The data revealed the paired treatment more than doubled the median time before disease progression when compared against current standard-of-care options.
Participants receiving the combination therapy achieved median PFS of 6.9 months. In contrast, those on standard treatment protocols managed only 3.1 months. This outcome successfully met the study’s primary objective.
The experimental regimen also demonstrated a 58% reduction in the hazard of disease advancement. Such figures typically capture significant attention from oncology-focused investors.
Impressive Results Beyond Primary Goals
Secondary outcome measures proved equally compelling. The overall response rate registered at 37.1% among patients receiving the darovasertib combination, contrasted sharply with merely 5.8% among those on standard care.
Five individuals in the experimental treatment group experienced complete responses. Meanwhile, the standard-care group recorded none whatsoever.
The median response duration for the combination treatment was 6.8 months. Researchers characterized the therapy as well-tolerated with a safety profile considered manageable.
Preliminary trends also indicated a potential overall survival advantage for the combination regimen compared to standard treatment, although comprehensive data on this metric remains immature.
Metastatic uveal melanoma has traditionally offered patients extremely limited effective therapeutic alternatives. These clinical findings establish darovasertib as a promising first-in-class treatment option for this condition.
Regulatory Submission Targeted for Second Half 2026
IDEAYA announced its intention to file a New Drug Application with the FDA during the second half of 2026, leveraging these trial outcomes.
This schedule suggests a potential regulatory approval decision arriving sometime throughout 2027, contingent upon the FDA’s review timeline.
IDYA stock climbed as high as 26.36% during premarket hours, touching $38.60, based on Benzinga Pro data. Earlier trading reports indicated gains hovering around 15%, with shares changing hands near $35.
The equity had previously been trading close to its 52-week peak of $41.02 before Monday’s news. Over the trailing twelve-month period, IDYA has appreciated approximately 78%.
Broader market sentiment was subdued Monday, with S&P 500 futures declining roughly 0.6% during the timeframe of the premarket advance.
IDEAYA intends to share comprehensive trial findings at a forthcoming medical conference, with additional details anticipated later throughout 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
